Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Boehringer Ingelheim
US Department of Justice
UBS
Daiichi Sankyo
Mallinckrodt
US Army
Healthtrust
Novartis
Teva

Generated: January 24, 2018

DrugPatentWatch Database Preview

COREG Drug Profile

« Back to Dashboard

Which patents cover Coreg, and what generic alternatives are available?

Coreg is a drug marketed by Smithkline Beecham and is included in two NDAs. There are two patents protecting this drug and three Paragraph IV challenges.

The generic ingredient in COREG is carvedilol phosphate. There are thirty-six drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the carvedilol phosphate profile page.

US Patents and Regulatory Information for COREG

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Smithkline Beecham COREG carvedilol TABLET;ORAL 020297-004 May 29, 1997 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Smithkline Beecham COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-002 Oct 20, 2006 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Smithkline Beecham COREG carvedilol TABLET;ORAL 020297-001 Sep 14, 1995 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Smithkline Beecham COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-004 Oct 20, 2006 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Smithkline Beecham COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-002 Oct 20, 2006 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Smithkline Beecham COREG carvedilol TABLET;ORAL 020297-003 Sep 14, 1995 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Smithkline Beecham COREG carvedilol TABLET;ORAL 020297-002 Sep 14, 1995 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Smithkline Beecham COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-001 Oct 20, 2006 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Smithkline Beecham COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-001 Oct 20, 2006 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Smithkline Beecham COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-003 Oct 20, 2006 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for COREG

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Smithkline Beecham COREG carvedilol TABLET;ORAL 020297-002 Sep 14, 1995 ➤ Subscribe ➤ Subscribe
Smithkline Beecham COREG carvedilol TABLET;ORAL 020297-001 Sep 14, 1995 ➤ Subscribe ➤ Subscribe
Smithkline Beecham COREG carvedilol TABLET;ORAL 020297-002 Sep 14, 1995 ➤ Subscribe ➤ Subscribe
Smithkline Beecham COREG carvedilol TABLET;ORAL 020297-004 May 29, 1997 ➤ Subscribe ➤ Subscribe
Smithkline Beecham COREG carvedilol TABLET;ORAL 020297-001 Sep 14, 1995 ➤ Subscribe ➤ Subscribe
Smithkline Beecham COREG carvedilol TABLET;ORAL 020297-003 Sep 14, 1995 ➤ Subscribe ➤ Subscribe
Smithkline Beecham COREG carvedilol TABLET;ORAL 020297-003 Sep 14, 1995 ➤ Subscribe ➤ Subscribe
Smithkline Beecham COREG carvedilol TABLET;ORAL 020297-002 Sep 14, 1995 ➤ Subscribe ➤ Subscribe
Smithkline Beecham COREG carvedilol TABLET;ORAL 020297-001 Sep 14, 1995 ➤ Subscribe ➤ Subscribe
Smithkline Beecham COREG carvedilol TABLET;ORAL 020297-003 Sep 14, 1995 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for COREG
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Extended-release Capsules 10 mg and 20 mg ➤ Subscribe 3/18/2008
➤ Subscribe Extended-release Capsules 40 mg ➤ Subscribe 12/21/2007
➤ Subscribe Extended-release Capsules 80 mg ➤ Subscribe 11/19/2007

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Chinese Patent Office
Harvard Business School
US Department of Justice
Federal Trade Commission
Moodys
Mallinckrodt
Cipla
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot